Latest Active Biotech News & Updates

See the latest news and media coverage for Active Biotech. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Active Biotech

Biotech company developing cancer and eye disease treatments

activebiotech.com
Headquarters
Lund, Sweden
Founded year
1998
Company type
Public company
Number of employees
2–20

Last updated

Latest news about Active Biotech

In short: Active Biotech reported a smaller-than-expected Q1 2026 loss while advancing clinical trials and securing new patents for tasquinimod and laquinimod.

Company announcements

  • Active Biotech

    Active Biotech publishes Q1 2026 interim report

    Reports operating loss of SEK 8.6M, cash at SEK 53.3M. Highlights patent grant and positive clinical feedback on tasquinimod.

  • Active Biotech

    Active Biotech publishes LION study results

    The phase I study shows topical laquinimod penetrates the eye's posterior segment, is well-tolerated, supporting development for inflammatory eye diseases.

  • Active Biotech

    Active Biotech invites shareholders to AGM

    The meeting occurs on May 20, 2026, in Lund. Proposals include board re-elections, reverse share split 1:100, and share issue authorization. No dividend proposed.

  • Active Biotech

    Active Biotech publishes preclinical data on tasquinimod

    Tasquinimod improves erythropoiesis and bone health in MDS model via collaboration with Dr. Manja Wobus. It supports MDS as expansion opportunity.

Unlock all announcements with a

Media coverage

  • FinanzNachrichten

    Active Biotech AB: Active Biotech Interim Report Q1 2026

    EVENTS DURING THE FIRST QUARTERThe US Patent Office (US PTO) granted a patent related to a pharmaceutical formulation of tasquinimod (January)Active Biotech receives positive feedback...

  • Dagens industri

    Smaller loss than expected for Active Biotech

    The research company Active Biotech reports an operating result of -8.6 million kronor for the first quarter of 2026 (-11.2).

  • Dagens industri

    Active Biotech minskar förlusten

    Forskningsbolaget Active Biotech redovisar ett rörelseresultat på -9,1 miljoner kronor för det fjärde kvartalet 2025 (-10,3).

  • London Stock Exchange

    Active Biotech announces outcome in the rights issue

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN...

Unlock all articles with a

Never miss news about Active Biotech

Track Active Biotech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Active Biotech competitors & trending companies

Browse news for competitors to Active Biotech and other trending companies.